Clene Change in Assets/Liabilities 2018-2025 | CLNN

Clene change in assets/liabilities from 2018 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities

Clene Change in Assets/Liabilities 2018-2025 | CLNN

Clene change in assets/liabilities from 2018 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$241.7B
Amgen (AMGN)$155.8B
Gilead Sciences (GILD)$149.1B
Vertex Pharmaceuticals (VRTX)$101.5B
Bristol Myers Squibb (BMY)$97.4B
CSL (CSLLY)$86.1B
GSK (GSK)$79.8B
Regeneron Pharmaceuticals (REGN)$59.5B
Alnylam Pharmaceuticals (ALNY)$56.7B
Argenex SE (ARGX)$39.6B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$26B
Royalty Pharma (RPRX)$20.5B
Biogen (BIIB)$19.8B
Incyte (INCY)$16.8B
Illumina (ILMN)$15.5B
Genmab (GMAB)$14.5B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.5B
Exelixis (EXEL)$10.4B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Bio-Techne Corp (TECH)$8.6B
Exact Sciences (EXAS)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Halozyme Therapeutics (HALO)$8B